Adaptive Randomized study of idarubicin and cytarabine (IA) alone or with interleukin 11 (IL-11) as induction therapy in patients aged 50 or above with untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (HR-MDS).

被引：0
|
作者：
Giles, F [1 ]
Kantarjian, H [1 ]
Cortes, J [1 ]
Tsimberidou, A [1 ]
Faderl, S [1 ]
Verstovsek, S [1 ]
Thomas, D [1 ]
Garcia-Manero, G [1 ]
Wierda, W [1 ]
Ferrajoli, A [1 ]
Kornblau, S [1 ]
Andreeff, M [1 ]
O'Brien, S [1 ]
Beran, M [1 ]
Estey, E [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4740
引用
收藏
页码：253B / 253B
页数：1
相关论文
共 50 条
  • [41] Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase 1/11 results of the EORTC/GIMEMA AML-14A trial
    Selleslag, Dominik
    Suciu, Stefan
    Meloni, Giovanna
    Muus, Petra
    Halkes, Constantijn J. M.
    Venditti, Adriano
    Ramadan, Safaa M.
    Pruijt, Hans
    Meert, Liv
    Vignetti, Marco
    Marie, Jean-Pierre
    Wittnebel, Sibastian
    de Witte, Theo
    Amadori, Sergio
    Willemze, Roelof
    Baron, Fridiric
    HAEMATOLOGICA, 2017, 102 (02) : E47 - E51
  • [42] A randomized, open-label, phase II study of azacitidine (AZA) in combination with durvalumab in patients (pts) with previously untreated higher-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) ineligible for hematopoietic stem cell transplantation (HSCT).
    Silverman, Lewis R.
    Dohner, Hartmut
    Dombret, Herve
    Mufti, Ghulam J.
    Stone, Richard M.
    Rose, Shelonitda
    Gerike, Torsten
    Camus, Frederic
    Fenaux, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] A randomized phase II trial of the tyrosine kinase inhibitor PKC412 in patients (pts) with acute myeloid leukemia (AML)/high-risk myelodysplastic syndromes (MDS) characterized by wild-type (WT) or mutated FLT3.
    Estey, EH
    Fisher, T
    Giles, F
    Feldman, EJ
    Ehninger, G
    Schiller, GJ
    Klimek, VM
    Nimer, SD
    De Angelo, DJ
    Gilliland, DG
    Fox, E
    Wang, YF
    Rosamilia, M
    Resta, D
    Cohen, P
    Stone, RM
    BLOOD, 2003, 102 (11) : 614A - 615A
  • [44] Randomized 3 arm phase III study of interleukin 3 (IL-3), or granulocyte/macrophage colony-stimulating factor (GM-CSF) as an adjuvant to low doses of cytosine arabinoside (LD-AraC) for the treatment of high-risk myelodysplastic syndromes (HR-MDS)
    Gerhartz, HH
    Zwierzina, H
    Suciu, S
    Walther, J
    Dardenne, M
    Neuwirtova, R
    Fenaux, P
    Beksac, M
    Harousseau, JL
    Louwagie, A
    Thyss, A
    Fiere, D
    Coiffier, B
    Baumelou, F
    Labar, B
    Solbu, G
    Willemze, R
    BLOOD, 1997, 90 (10) : 370 - 370
  • [45] Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS)
    Wei, Andrew H.
    Breccia, Massimo
    Ooi, Melissa
    Romero, Maria Teresa Cedena
    Ciceri, Fabio
    Erba, Harry P.
    Gaur, Anil
    Sechaud, Romain
    Halilovic, Ensar
    Kuenzle, Brigitte
    Fabre, Claire
    Porkka, Kimmo
    BLOOD, 2021, 138
  • [46] Randomized-3 armed phase III study of interleukin 3 (IL-3), or granulocyte/macrophage colony-stimulating factor (GM-CSF) as an adjuvant to low doses of cytosine arabinoside (LD-ARAC) for the treatment of high-risk myelodysplastic syndromes (HR-MDS).
    Gerhartz, HH
    Walther, JH
    Neuwirtova, R
    Fenaux, P
    Harousseau, JL
    Beksac, M
    Zwierzina, H
    Baumelou, E
    Fiere, D
    Louwagie, A
    Thyss, A
    Dardenne, M
    Solbu, G
    Suciu, S
    Zittoun, R
    BLOOD, 1996, 88 (10) : 2309 - 2309
  • [47] An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)
    Stein, Anthony S.
    Bajel, Ashish
    Fleming, Shaun
    Jongen-Lavrencic, Mojca
    Garciaz, Sylvain
    Maiti, Abhishek
    Boissel, Nicolas
    De Botton, Stephane
    Huls, Gerwin A.
    de Leeuw, David C.
    Avigan, David
    Jensen, Kyle
    Demers, Brigitte
    Wagenaar, Timothy
    Mi, Gu
    Ziti-Ljajic, Samira
    Draganov, Dobrin
    Abbadessa, Giovanni
    Wei, Andrew H.
    BLOOD, 2022, 140 : 7476 - 7477
  • [48] Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study
    Zeidan, Amer M.
    Cavenagh, James
    Voso, Maria Teresa
    Taussig, David
    Tormo, Mar
    Boss, Isaac
    Copeland, Wilbert B.
    Gray, Vanessa E.
    Previtali, Alessandro
    O'Connor, Tim
    Rose, Shelonitda
    Beach, C. L.
    Silverman, Lewis R.
    BLOOD, 2019, 134
  • [49] Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat
    Pagel, John M.
    Othus, Megan
    Garcia-Manero, Guillermo
    Fang, Min
    Radich, Jerald P.
    Rizzieri, David A.
    Marcucci, Guido
    Strickland, Stephen A.
    Litzow, Mark
    Savoie, Mary Lynn
    Spellman, Stephen R.
    Confer, Dennis L.
    Chell, Jeffrey
    Brown, Maria
    Medeiros, Bruno C.
    Sekeres, Mikkael A.
    Lin, Tara L.
    Uy, Geoffrey L.
    Powell, Bayard L.
    Kolitz, Jonathan E.
    Larson, Richard A.
    Stone, Richard M.
    Claxton, David F.
    Essell, James
    Luger, Selina
    Mohan, Sanjay R.
    Moseley, Anna
    Erba, Harry P.
    Appelbaum, Frederick R.
    BLOOD, 2016, 128 (22)
  • [50] A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612
    Assouline, Sarit
    Michaelis, Laura C.
    Othus, Megan
    Hay, Annette E.
    Walter, Roland B.
    Jacoby, Meagan A.
    Schroeder, Mark A.
    Uy, Geoffrey L.
    Law, Lisa Y.
    Cheema, Faisal
    Sweet, Kendra L.
    Asch, Adam S.
    Liu, Jijun
    Moseley, Anna B.
    Maher, Tracy
    Kingsbury, Laura L.
    Fang, Min
    Radich, Jerald
    Little, Richard F.
    Erba, Harry P.
    LEUKEMIA & LYMPHOMA, 2023, 64 (02) : 473 - 477
12345